Drug Recall
Terminated
Historical recordClass II
Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5 mg/325 mg per 15 mL C-II, a) 4 fl.oz .(120 mL), 12 bottles per case (NDC 66689-023-04), b) 16 fl.oz. (473 mL), 12 bottles per case (NDC 66689-023-16), c) 50 unit dose cups of 15 mL per case, (NDC No. 66689-023-50), Rx only, Manufactured by VistaPharm, Largo, FL 33771
by VistaPharm, Inc.
- Reason
- CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.
- Recall initiated
- January 18, 2017
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass II
Nystatin Oral Suspension, USP 100,000 units per mL, a) 2 fl. oz. (60 mL), 24 bottles per case (NDC 66689-008-02), b) 16 fl. oz. (237 mL), 12 bottles per case (NDC 66689-008-16), Rx only, Manufactured by VistaPharm, Largo, FL 33771
by VistaPharm, Inc.
- Reason
- CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.
- Recall initiated
- January 18, 2017
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass II
MIDAZOLAM INJECTION, USP, *25 mg/5 mL, (5 mg/ mL), 5 mL vials, 10 Vials per carton, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173 --- NDC 63323-412-05
by Fresenius Kabi USA, LLC
- Reason
- Failed Impurities/Degradation Specifications
- Recall initiated
- December 16, 2016
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide and Puerto Rico
View recall →
Drug Recall
Terminated
Historical recordClass II
Sun Pharma Carbidopa and Levodopa Tablets USP 25 mg/250 mg a) 100-count bottles (NDC 62756-519-88), b) 500-count bottles (NDC 62756-519-13) Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway, Halol-389 350 Gujarat, India.
by Sun Pharmaceutical Industries, Inc.
- Reason
- Failed Dissolution Specifications
- Recall initiated
- January 12, 2017
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass III
Endure 400 Scrub-Stat (chlorhexidine gluconate) Foam Forming Solution, 4%, packaged in plastic (HDPE) bottles, Over-the-counter, Model Number: 61430436 (800 mL, 12 bottles/case) - United States; Model Number: 6000179 (800 mL, 12 bottles/case) - Canada, Ecolab, St. Paul, MN 55102, NDC 47593-265-36
by Ecolab, Inc.
- Reason
- Subpotent Drug
- Recall initiated
- December 2, 2016
- Reported by FDA
- February 8, 2017
- Distribution
- United States, Puerto Rico and Canada
View recall →
Drug Recall
Terminated
Historical recordClass III
Finasteride Tablets, USP 5 mg, 90-count bottles, Rx only, Manufactured for : Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: Hetero Hetero Labs, Unit V Polepally, Jadcheria, Mahaboob Nagar - 509 301, India Limited NDC 31722-525-90
by Hetero Drugs Ltd. - Unit 1
- Reason
- Failed Tablet/Capsule Specification: Tablets were found to be twice the thickness in one lot of product.
- Recall initiated
- December 29, 2016
- Reported by FDA
- February 8, 2017
- Distribution
- NJ only.
View recall →
Drug Recall
Terminated
Historical recordClass II
Flucanozole Tablets, USP, 200 mg, a) 30 count (NDC 55111-146-30) and b) 100 count (NDC 55111-146-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India
by Dr. Reddy's Laboratories, Inc.
- Reason
- Failed Dissolution Specifications; 18 month stability time point
- Recall initiated
- December 28, 2016
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass II
Flucanozole Tablets, USP, 150 mg, 12x1 Blister cards, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India --- NDC 55111-145-12
by Dr. Reddy's Laboratories, Inc.
- Reason
- Failed Dissolution Specifications; 18 month stability time point
- Recall initiated
- December 28, 2016
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass II
Flucanozole Tablets, USP, 100 mg, a) 30 count (NDC 55111-144-30) and b) 100 count (NDC 55111-144-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India
by Dr. Reddy's Laboratories, Inc.
- Reason
- Failed Dissolution Specifications; 18 month stability time point
- Recall initiated
- December 28, 2016
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass II
Flucanozole Tablets, USP, 50 mg, a) 30 count (NDC 55111-143-30) and b) 100 count (NDC 55111-143-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India
by Dr. Reddy's Laboratories, Inc.
- Reason
- Failed Dissolution Specifications; 18 month stability time point
- Recall initiated
- December 28, 2016
- Reported by FDA
- February 8, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass III
Azelastine Hydrochloride Nasal Solution (Nasal Spray), 0.1% (137 mcg per spray), packaged in 30 mL bottles, Rx only, Distributed by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724, NDC 0054-0293-99
by Roxane Laboratories, Inc.
- Reason
- Defective Delivery System: out of specification result for droplet size distribution at the d90 measurement testing during the 6 month time point..
- Recall initiated
- December 14, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide and Puerto Rico.
View recall →
Drug Recall
Terminated
Historical recordClass II
Mesalamine, U.S.P. [CAS 89-57-6] Cambrex Charles City, Inc. Charles City, IA packaged in double lined PE liners inside Poly-lined cardboard drums. Net weight 40 kg
by Cambrex Charles City Inc
- Reason
- Presence of Particulate Matter: Stainless steel in a chemical reactor dissolved into the API solution and was detected in the finished product.
- Recall initiated
- May 20, 2014
- Reported by FDA
- February 1, 2017
- Distribution
- Product distributed solely to the state of Minnesota.
View recall →
Drug Recall
Terminated
Historical recordClass III
buPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, 60 count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India NDC 47335-0738-86
by Sun Pharmaceutical Industries, Inc.
- Reason
- Failed Dissolution Specifications; 18 month stability time point
- Recall initiated
- December 20, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass III
buPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, a) 60 (NDC 47335-737-86), b) 100 (NDC 47335-737-88) and c) 500 (NDC 47335-737-13) count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India
by Sun Pharmaceutical Industries, Inc.
- Reason
- Failed Dissolution Specifications; 18 month stability time point
- Recall initiated
- December 20, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide
View recall →
Drug Recall
Terminated
Historical recordClass II
Temozolomide Capsules, 250 mg, 5-count bottles, Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA, NDC 0378-5265-98.
by Mylan LLC.
- Reason
- Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
- Recall initiated
- December 20, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide in the USA
View recall →
Drug Recall
Terminated
Historical recordClass II
Temozolomide Capsules, 180 mg, packaged in a) 5-count bottles (NDC 0378-5264-98), b) 14-count bottles (NDC 0378-5264-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.
by Mylan LLC.
- Reason
- Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
- Recall initiated
- December 20, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide in the USA
View recall →
Drug Recall
Terminated
Historical recordClass II
Temozolomide Capsules, 140 mg, packaged in a) 5-count bottles (NDC 0378-5263-98), b) 14-count bottles (NDC 0378-5263-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.
by Mylan LLC.
- Reason
- Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
- Recall initiated
- December 20, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide in the USA
View recall →
Drug Recall
Terminated
Historical recordClass II
Temozolomide Capsules, 100 mg, packaged in a) 5-count bottles (NDC 0378-5262-98), b) 14-count bottles (NDC 0378-5262-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.
by Mylan LLC.
- Reason
- Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
- Recall initiated
- December 20, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide in the USA
View recall →
Drug Recall
Terminated
Historical recordClass II
Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in a 100 mL bottle, Rx only, Manufactured for: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960, NDC 0093-4150-73
by Teva Pharmaceuticals USA
- Reason
- Subpotency: due to a low, out of specification test result for assay during stability testing.
- Recall initiated
- December 21, 2016
- Reported by FDA
- February 1, 2017
- Distribution
- United States and Puerto Rico
View recall →
Drug Recall
Terminated
Historical recordClass III
Albuterol Sulfate Inhalation Solution, USP, 0.021% (0.63 mg / 3 mL), 3mL Vials, Rx only, Mfd. for Watson Laboratories Inc., Corona, CA 92880 USA, Mfd. by Cipla Ltd. Verna, Goa India, NDC 0591-3467-53
by Actavis Inc
- Reason
- Failed Impurities/Degradation Specifications: Product is out of specification for a known degradant.
- Recall initiated
- January 12, 2017
- Reported by FDA
- February 1, 2017
- Distribution
- Nationwide in the US
View recall →
This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace
does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice --
always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take.
Read the full medical disclaimer.